Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: Results from a 1-year open-label study

CNS Spectrums

Volumn 23, Issue 1, 2018, Pages 39-50

  Cutler, Andrew J ^a   Durgam, Suresh ^b   Wang, Yao ^b   Migliore, Raffaele ^b   Lu, Kaifeng ^b   Laszlovszky, Istvan ^c   Németh, Gyorgy ^c  

^a Meridien Research   (United States)

^b Allergan plc   (United States)

^c GEDEON RICHTER LTD   (Hungary)

Author keywords

antipsychotics; Cariprazine; dopamine receptors; long term safety; schizophrenia

Indexed keywords

CARIPRAZINE; CREATINE KINASE; PLACEBO; PROLACTIN; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; BODY WEIGHT; BODY WEIGHT GAIN; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIGESTIVE TRACT PARAMETERS; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; CLINICAL TRIAL; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HEADACHE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PIPERAZINES; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA; SLEEP INITIATION AND MAINTENANCE DISORDERS; WEIGHT GAIN;

EID: 85018387957     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852917000220     Document Type: Article

References (38)

1. Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis. 1999; 187(8): 496-502.
2. Weber NS, Cowan DN, Millikan AM, Niebuhr DW. Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey. Psychiatr Serv. 2009; 60(8): 1059-1067. Available at: http://ps. psychiatryonline. org/doi/pdf/ 10. 1176/ps. 2009. 60. 8. 1059.
3. De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006; 83(1): 87-93.
4. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012; 25(2): 83-88.
5. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials. Schizophr Res. 1999; 35(1): 51-68.
6. Weiden PJ. EPS profiles: The atypical antipsychotics are not all the same. J Psychiatr Pract. 2007; 13(1): 13-24.
7. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209-1223. Available at: http://www. nejm. org/doi/pdf/10. 1056/NEJMoa051688.
8. Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016; 173(3): 271-281.
9. Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016; 77(3): 371-378.
10. Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: A randomised, doubleblind, controlled trial. Lancet. 2017; pii: S0140-6736(17): 30060-0. Epub ahead of print Feb 6.
11. Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010; 333(1): 328-340. Available at: http://jpet. Aspetjournals. org/content/ 333/1/328.
12. Kiss B, Horti F, Bobok A. Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Schizophr Res. 2012; 136(8 Suppl 1): S190.
13. Slifstein M, Abi-Dargham A, D'Souza DC, et al. Cariprazine demonstrates high dopamine D3 and D2 receptor occupancy in patients with schizophrenia: A clinical PET study with [11C]-( + )-PHNO. Neuropsychopharmacology. 2013; 38: S520-S521.
14. Seneca N, Finnema SJ, Laszlovszky I, et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl). 2011; 218(3): 579-587. Available at: https://www. ncbi. nlm. nih. gov/pmc/articles/PMC3210913/.
15. Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. Schizophr Res. 2014; 152(2-3): 450-457. Available at: http://www. schres-journal. com/article/S0920-9964(13)00658-0/pdf.
16. Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: A fixed-dose, phase III, randomized, double-blind, placebo-and active-controlled trial. J Clin Psychiatry. 2015; 76(12): e1574-e1582. Available at: http://www. psychiatrist. com/jcp/ article/Pages/2015/v76n12/v76n1201. Aspx.
17. Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015; 35(4): 367-373.
18. Durgam S, Greenberg W, Li D, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology (Berl). 2017; 234(2): 199-209. Available at: https://www. ncbi. nlm. nih. gov/pmc/articles/ PMC5203812/.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
20. Kay SR, Opler LA, Spitzer RL, Williams JB, Fiszbein A, Gorelick A. SCID-PANSS: Two-tier diagnostic system for psychotic disorders. Compr Psychiatry. 1991; 32(4): 355-361.
21. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261-276.
22. Guy W. The Clinician Global Severity and Impression Scales: ECDEU Assessment Manual for Psychopharmacology. DHEW Publication no. 76-338. Rockville, MD: National Institute of Mental Health; 1976: 218-222.
23. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12): 1266-1277. Available at: https:// www. ncbi. nlm. nih. gov/pmc/articles/PMC3893686/.
24. Guy W. The AbnormalMovement Scale: ECDEUAssessment Manual for Psychopharmacology. DHEW Publication no. 76-338. Rockville, MD: National Institute of Mental Health; 1976: 218-222.
25. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154: 672-676.
26. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970; 212: 11-19.
27. Food and Drug Administration. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. Washington, DC: U. S. Department of Health and Human Services; 2009. Available at: http://www. fda. gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM174090. pdf.
28. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: A 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 189(2): 259-266.
29. Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr. 2013; 18(1): 43-54.
30. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assunção-Talbott S. Akathisia: An updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009; 70(5): 627-643.
31. Keks NA, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br J Psychiatry. 2007; 191(2): 131-139. Available at: http://bjp. rcpsych. org/ content/191/2/131.
32. Arato M, O'Connor R, Meltzer H, ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: The Ziprasidone Extended Use in Schizophrenia (ZEUS) Study. Int Clin Psychopharmacol. 2002; 17(5): 207-215.
33. Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009; 65(6): 510-517.
34. Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: A 6-month, open-label, extension study. J Clin Psychiatry. 2013; 74(5): 507-515. Available at: http://www. psychiatrist. com/ JCP/article/Pages/2013/v74n05/v74n0516. Aspx.
35. Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: A 12-month, doubleblind, active-controlled study. Int Clin Psychopharmacol. 2012; 27(3): 165-176.
36. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. J Clin Psychiatry. 2007; 8(Suppl 1): 20-27.
37. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry. 2007; 164(7): 1050-1060. Available at: http://ajp. psychiatryonline. org/doi/pdf/10. 1176/ajp. 2007. 164. 7. 1050.
38. Lee SY, Park MH, Patkar AA, Pae CU. Aretrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(2): 490-496.